Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-01-11 Purchase(A) |
2022-03-17 5:14 pm |
Amylyx Pharmaceuticals Inc. | AMLX | Morningside Venture Investments Ltd MVIL LLC 10% Owner |
263,158 | $19 | $5,000,002 | 10,678,808 (Indirect) |
View |
| 2022-01-11 Purchase |
2022-01-25 4:46 pm |
Amylyx Pharmaceuticals Inc. | AMLX | Morningside Venture Investments Ltd 10% Owner |
263,158 | $19 | $5,000,002 | 10,678,808 (Direct) |
View |
| 2022-01-11 Purchase |
2022-01-13 9:05 pm |
Amylyx Pharmaceuticals Inc. | AMLX | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities GP LLC Viking Global Opportunities Parent GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner |
2,300,000 | $19 | $43,700,000 | 2,300,000 (Indirect) |
View |
| 2022-01-06 Purchase |
2022-01-10 8:37 pm |
Amylyx Pharmaceuticals Inc. | AMLX | FONTEYNE PAUL R. Director |
3,947 | $19 | $74,993 | 12,347 (Direct) |
View |
| 2022-01-06 Purchase |
2022-01-10 8:35 pm |
Amylyx Pharmaceuticals Inc. | AMLX | Cheng Isaac Director |
6,578 | $19 | $124,982 | 10,430,628 (Indirect Direct) |
View |
| 2022-01-06 Purchase |
2022-01-10 8:34 pm |
Amylyx Pharmaceuticals Inc. | AMLX | MILNE GEORGE M JR Director |
26,315 | $19 | $499,985 | 229,796 (Direct) |
View |
| 2022-01-06 Purchase |
2022-01-10 8:30 pm |
Amylyx Pharmaceuticals Inc. | AMLX | Olinger Margaret Chief Commercial Officer |
6,842 | $19 | $129,998 | 344,258 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2022-01-11 Conversion |
2022-05-05 4:46 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | ALS Invest 1 B.V. 10% Owner |
5,955,889 | $0 | 5,955,889 (Direct) |
View |
Ownership |
2022-05-05 4:42 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | ALS Invest 1 B.V. 10% Owner |
0 | $0 | 5,955,889 (Direct) |
View |
| 2022-02-11 Option Award |
2022-03-28 4:30 pm |
N/A 2032-02-11 |
Amylyx Pharmaceuticals Inc. | AMLX | FRATES JAMES M Chief Financial Officer |
25,000 | $0 | 25,000 (Direct) |
View |
| 2022-01-11 Conversion(A) |
2022-03-17 5:14 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Morningside Venture Investments Ltd MVIL LLC 10% Owner |
20,831,300 | $0 | 10,678,808 (Indirect) |
View |
Ownership(A) |
2022-03-17 5:14 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Morningside Venture Investments Ltd MVIL LLC 10% Owner |
0 | $0 | 10,415,650 (Indirect) |
View |
| 2022-02-22 Option Award |
2022-02-28 5:05 pm |
N/A 2032-02-22 |
Amylyx Pharmaceuticals Inc. | AMLX | Mazzariello Gina Chief Legal Officer |
223,000 | $0 | 223,000 (Direct) |
View |
| 2022-01-11 Conversion |
2022-01-25 4:46 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Morningside Venture Investments Ltd 10% Owner |
20,831,300 | $0 | 10,678,808 (Direct) |
View |
Ownership |
2022-01-25 4:45 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Morningside Venture Investments Ltd 10% Owner |
0 | $0 | 10,415,650 (Direct) |
View |
Ownership |
2022-01-21 5:10 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | DRAGSA 96 LLC 10% Owner |
0 | $0 | 2,300,000 (Direct) |
View |
| 2022-11-11 Conversion |
2022-01-13 9:05 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities GP LLC Viking Global Opportunities Parent GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner |
9,741,072 | $0 | 2,300,000 (Indirect) |
View |
Ownership |
2022-01-11 8:46 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | VIKING GLOBAL INVESTORS LP Ott David C. HALVORSEN OLE ANDREAS Shabet Rose Sharon Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities GP LLC Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities Parent GP LLC 10% Owner |
0 | $0 | 4,870,536 (Indirect) |
View |
| 2022-01-06 Option Award |
2022-01-10 8:37 pm |
N/A 2032-01-06 |
Amylyx Pharmaceuticals Inc. | AMLX | FONTEYNE PAUL R. Director |
8,400 | $0 | 12,347 (Direct) |
View |
| 2022-01-06 Conversion |
2022-01-10 8:35 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Cheng Isaac Director |
10,415,650 | $0 | 10,430,628 (Indirect) |
View |
| 2022-01-06 Option Award |
2022-01-10 8:35 pm |
N/A 2032-01-06 |
Amylyx Pharmaceuticals Inc. | AMLX | Cheng Isaac Director |
8,400 | $0 | 10,430,628 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-10 8:34 pm |
N/A 2032-01-06 |
Amylyx Pharmaceuticals Inc. | AMLX | Yeramian Patrick D Chief Medical Officer |
155,833 | $0 | 333,833 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-10 8:34 pm |
N/A 2032-01-06 |
Amylyx Pharmaceuticals Inc. | AMLX | MILNE GEORGE M JR Director |
8,400 | $0 | 229,796 (Direct) |
View |
| 2022-01-06 Conversion |
2022-01-10 8:32 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Cohen Joshua B Co-Chief Executive Officer |
4,870 | $0 | 2,901,565 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-10 8:32 pm |
N/A 2032-01-06 |
Amylyx Pharmaceuticals Inc. | AMLX | Cohen Joshua B Co-Chief Executive Officer |
412,500 | $0 | 2,901,565 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-10 8:31 pm |
N/A 2032-01-06 |
Amylyx Pharmaceuticals Inc. | AMLX | Quimi Daphne Director |
8,400 | $0 | 8,400 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-10 8:30 pm |
N/A 2032-01-06 |
Amylyx Pharmaceuticals Inc. | AMLX | Olinger Margaret Chief Commercial Officer |
155,833 | $0 | 344,258 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-10 8:28 pm |
N/A 2032-01-06 |
Amylyx Pharmaceuticals Inc. | AMLX | FRATES JAMES M Chief Financial Officer |
174,167 | $0 | 174,167 (Direct) |
View |
| 2022-01-06 Conversion |
2022-01-10 8:28 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Klee Justin B. Co-Chief Executive Officer |
4,870 | $0 | 2,901,565 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-10 8:28 pm |
N/A 2032-01-06 |
Amylyx Pharmaceuticals Inc. | AMLX | Klee Justin B. Co-Chief Executive Officer |
412,500 | $0 | 2,901,565 (Direct) |
View |
Ownership |
2022-01-06 5:21 pm |
N/A 2031-01-25 |
Amylyx Pharmaceuticals Inc. | AMLX | FRATES JAMES M Chief Financial Officer |
0 | $0 | 452,000 (Direct) |
View |
Ownership |
2022-01-06 5:10 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Cohen Joshua B Co-Chief Executive Officer |
0 | $0 | 3,123,585 (Direct) |
View |
Ownership |
2022-01-06 5:09 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Cheng Isaac Director |
0 | $0 | 10,415,650 (Indirect) |
View |
Ownership |
2022-01-06 5:07 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Olinger Margaret Chief Commercial Officer |
0 | $0 | 336,160 (Direct) |
View |
Ownership |
2022-01-06 5:06 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Klee Justin B. Co-Chief Executive Officer |
0 | $0 | 3,123,585 (Direct) |
View |
Ownership |
2022-01-06 5:06 pm |
N/A 2031-03-23 |
Amylyx Pharmaceuticals Inc. | AMLX | FONTEYNE PAUL R. Director |
0 | $0 | 81,100 (Direct) |
View |
Ownership |
2022-01-06 5:05 pm |
N/A 2031-06-21 |
Amylyx Pharmaceuticals Inc. | AMLX | Quimi Daphne Director |
0 | $0 | 81,100 (Direct) |
View |
Ownership |
2022-01-06 5:03 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | MILNE GEORGE M JR Director |
0 | $0 | 886,506 (Direct) |
View |
Ownership |
2022-01-06 5:02 pm |
N/A N/A |
Amylyx Pharmaceuticals Inc. | AMLX | Yeramian Patrick D Chief Medical Officer |
0 | $0 | 338,296 (Direct) |
View |